Results 121 to 130 of about 16,400 (167)

Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B-cell malignancies. [PDF]

ESMO Open
Zhu J, Li J, Tam CS, Wang L, Xu J, Zhang J, Khanna P, Qiu L.   +7 more
europepmc   +1 more source

No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12. [PDF]

Blood Adv
Laurenti L, Guglielmi F, Mosca A, Vitale C, Montalbano MC, Favrin G, Ferrarini I, Galitzia A, Pasquale R, Moratti M, Catania G, Murru R, Giannarelli D, Martino EA, Moia R, Zucchetto A, Tissino E, Autore F, Tomasso A, Stirparo L, Quaranta T, Abbate PL, Gattei V, Gaidano G, Gentile M, Krampera M, Farina G, Visentin A, Innao V, Varettoni M, Coscia M, Innocenti I.   +31 more
europepmc   +1 more source

Economic Evaluation of Bruton's Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa. [PDF]

Appl Health Econ Health Policy
Woudberg R, Sinanovic E.
europepmc   +1 more source

A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study.

Blood
Itsara A, Rogness VM, Samples L, Yuan CM, Wang HW, Ahn IE, Farooqui MZH, Tian X, Sun C, Tomasulo E, Soto S, Superata J, Bezkorovaynaya L, Hughes TE, Nierman P, Wiestner A.   +15 more
europepmc   +1 more source

Brute force: the effects of ibrutinib on brexu-cel. [PDF]

Blood Adv
Peterson CE, Betts BC.
europepmc   +1 more source

Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma. [PDF]

Blood Adv
Phillips T, Di M, Miller TA, Wang J, Pierre A, Maglinte GA, Seymour EK, Wang Y.   +7 more
europepmc   +1 more source

Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. [PDF]

Blood Adv
Darnell EP, Gallagher KME, Kanska J, Scarfò I, Balderrama-Gutierrez G, Berger TR, Budka J, Bozym DJ, Huang T, Shen R, Leick MB, Maus MV.   +11 more
europepmc   +1 more source

Cutaneous Adverse Effects in Patients Treated with BTK Inhibitors. [PDF]

Cancers (Basel)
Robak E, Robak T.
europepmc   +1 more source

High-Risk Chronic Lymphocytic Leukemia in a Young Adult Treated With Reduced-Dosage, Fixed-Duration Ibrutinib and Venetoclax. [PDF]

J Med Cases
Gutierrez CLD, Quero-Taggaoa AKH, Uy TCF, Veloso JAD.   +3 more
europepmc   +1 more source

Targeting the BMX in cancer: molecular mechanisms and emerging therapeutic strategies. [PDF]

J Enzyme Inhib Med Chem
Zhang M, Chen J, Liang R, Jiang W, Lin M, Wen S, Liu D, Yi B, Chen R, Chen T, Li Z.   +10 more
europepmc   +1 more source